CD30 expression in oral and oropharyngeal diffuse large b cell lymphoma, not otherwise specified

Página do item simplificado
dc.creatorAna Luísa Morais Perdigão
dc.creatorRommel Mario Rodríguez Burbano
dc.creatorFelipe Paiva Fonseca
dc.creatorCarla Isabelly Rodrigues-Fernandes
dc.creatorGabriela Ribeiro Araújo
dc.creatorCiro Dantas Soares
dc.creatorBruno Augusto Benevenuto de Andrade
dc.creatorManoela Domingues Martins
dc.creatorPablo Agustin Vargas
dc.creatorHélder Antônio Rebelo Pontes
dc.creatorFábio Ramôa Pires
dc.date.accessioned2023-11-28T21:31:11Z
dc.date.accessioned2025-09-09T00:41:31Z
dc.date.available2023-11-28T21:31:11Z
dc.date.issued2021-10-16
dc.identifier.doihttps://doi.org/10.1007/s12105-021-01387-5
dc.identifier.issn19360568
dc.identifier.urihttps://hdl.handle.net/1843/61491
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofHead and Neck Pathology
dc.rightsAcesso Restrito
dc.subjectKi-1 antigen
dc.subjectLymphoma
dc.subjectLymphoma, large B-Cell, diffuse
dc.subjectHead
dc.subjectNeck
dc.subjectMouth
dc.subjectOropharynx
dc.subjectSurvival rate
dc.subjectImmunohistochemistry
dc.subject.otheracesso restrito springer fao clínica Cd30 expression in oral and oropharyngeal diffuse large b cell lymphoma, not otherwise specified assunto Lymphoma busca dia 09 do 11 2023
dc.subject.othertítulo periódico Head and neck pathology data 16 outubro ano 2021
dc.titleCD30 expression in oral and oropharyngeal diffuse large b cell lymphoma, not otherwise specified
dc.typeArtigo de periódico
local.citation.epage485
local.citation.issue2
local.citation.spage476
local.citation.volume16
local.description.resumoDiffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS) is the most frequent non-Hodgkin lymphoma subtype. This aggressive neoplasm may variably express the CD30 protein, which may be used as a therapeutic target for this tumor. However, CD30 expression in DLBCL NOS arising from the oral cavity and the oropharynx has not been investigated. Therefore, this study aims to determine the frequency of CD30 expression and its prognostic significance for patients affected by oral/oropharyngeal DLBCL NOS. Fifty cases were retrieved from pathology files and submitted to immunohistochemistry against CD30. Reactivity was accessed by two oral pathologists using two cut-off values (> 0% and > 20% of tumor cells) to determine positivity in each case. Clinical data were obtained from the patients' medical files to investigate the prognostic potential of the protein. Seven high-grade B cell lymphomas and two EBV-positive DLBCL NOS were identified. We found one CD30-positive case in each of these two groups of lymphomas. Among the remaining 41 DLBCL NOS, other four cases (three in the oral cavity and one in the oropharynx) were positive for CD30, but only two expressed the protein in > 20% of tumor cells, both in the oral cavity. Survival analysis demonstrated that CD30-positive cases had a higher five-year overall survival rate (75%) than CD30-negative cases (32.3%), although a statistically significant result was not achieved (p = 0.19). Only a minor subset of oral and oropharyngeal DLBCL NOS express CD30 and these patients seems to have a higher survival rate.
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.initialsUFMG
local.url.externahttps://link.springer.com/article/10.1007/s12105-021-01387-5

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
978 B
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG